Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer’s disease
Author
dc.contributor.author
Gerakis, Yannis
Author
dc.contributor.author
Hetz Flores, Claudio
Admission date
dc.date.accessioned
2018-07-19T22:12:18Z
Available date
dc.date.available
2018-07-19T22:12:18Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
FEBS Journal, 285 (2018): 995–1011
es_ES
Identifier
dc.identifier.other
10.1111/febs.14332
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/150023
Abstract
dc.description.abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by synaptic dysfunction and accumulation of abnormal aggregates formed by amyloid- peptides or phosphorylated tau proteins. Accumulating evidence suggests that alterations in the buffering capacity of the proteostasis network are a salient feature of AD. The endoplasmic reticulum (ER) is the main compartment involved in protein folding and secretion and is drastically affected in AD neurons. ER stress triggers the activation of the unfolded protein response (UPR), a signal transduction pathway that enforces adaptive programs to recover homeostasis or trigger apoptosis of irreversibly damaged cells. Experimental manipulation of specific UPR signaling modules in preclinical models of AD has revealed a key role of this pathway in regulating protein misfolding and neurodegeneration. Recent studies suggest that the UPR also influences synaptic plasticity and memory through ER stress-independent mechanisms. Consequently, targeting of the UPR in AD is emerging as an interesting therapeutic approach to modify the two pillars of AD, protein misfolding and synaptic failure. Here, we review the functional role of ER stress signaling in AD, discussing the complex involvement of the pathway in controlling neuronal survival, the amyloid cascade, neurodegeneration and synaptic function. Recent intervention efforts to target the UPR with pharmacological and gene therapy strategies are also discussed.
es_ES
Patrocinador
dc.description.sponsorship
FONDAP Program
15150012
US Office of Naval Research-Global (ONR-G)
N62909-16-1-2003
Millennium Institute
P09-015-F
FONDEF
ID16I10223
D11E1007
US Air Force Office of Scientific Research
FA9550-16-1-0384
CONICYT-Brazil
441921/2016-7
ALS Therapy Alliance
2014-F-059
Muscular Dystrophy Association
382453
Michael J. Fox Foundation for Parkinson's Research - Target Validation
9277
FONDECYT
1140549
ALSRP Therapeutic Idea Award
AL150111